Tags

Type your tag names separated by a space and hit enter

Muscle and statins: from toxicity to the nocebo effect.
Expert Opin Drug Saf. 2019 07; 18(7):573-579.EO

Abstract

INTRODUCTION

Although statins have a satisfactory safety profile and are well tolerated, many statin-treated patients report muscle symptoms in clinical practice which contribute to drug discontinuation and, consequently, adverse cardiovascular outcomes.

AREAS COVERED

This narrative review will cover the definition and prevalence of statin intolerance, the clinical spectrum of statin-associated muscle symptoms (SAMS) with special focus on patients with only mild myalgias, the complexity of statin muscle intolerance diagnosis and provide an overview on the nocebo effect of particular importance for physicians.

EXPERT OPINION

Many patients are unable to tolerate statin therapy, with SAMS being the most common cause of statin intolerance. The reported incidence of SAMS was consistently lower in randomized placebo-controlled trials than in observational studies. These results strongly suggested that SAMS were not always due to by the pharmacologic effects of statin therapy. Convincing patients that their muscle symptoms might be due to causes other than statin treatment is sometimes difficult. Furthermore, clinicians should not prematurely discontinue statin therapy before considering other possible causes, including the nocebo effect.

Authors+Show Affiliations

a Lipid and Vascular Risk Unit, Endocrinology and Nutrition Department , Hospital del Mar , Barcelona , Spain. b Department of Medicine , Universitat Autònoma de Barcelona , Barcelona , Spain.a Lipid and Vascular Risk Unit, Endocrinology and Nutrition Department , Hospital del Mar , Barcelona , Spain. b Department of Medicine , Universitat Autònoma de Barcelona , Barcelona , Spain.a Lipid and Vascular Risk Unit, Endocrinology and Nutrition Department , Hospital del Mar , Barcelona , Spain. b Department of Medicine , Universitat Autònoma de Barcelona , Barcelona , Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31070941

Citation

Pedro-Botet, Juan, et al. "Muscle and Statins: From Toxicity to the Nocebo Effect." Expert Opinion On Drug Safety, vol. 18, no. 7, 2019, pp. 573-579.
Pedro-Botet J, Climent E, Benaiges D. Muscle and statins: from toxicity to the nocebo effect. Expert Opin Drug Saf. 2019;18(7):573-579.
Pedro-Botet, J., Climent, E., & Benaiges, D. (2019). Muscle and statins: from toxicity to the nocebo effect. Expert Opinion On Drug Safety, 18(7), 573-579. https://doi.org/10.1080/14740338.2019.1615053
Pedro-Botet J, Climent E, Benaiges D. Muscle and Statins: From Toxicity to the Nocebo Effect. Expert Opin Drug Saf. 2019;18(7):573-579. PubMed PMID: 31070941.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Muscle and statins: from toxicity to the nocebo effect. AU - Pedro-Botet,Juan, AU - Climent,Elisenda, AU - Benaiges,David, Y1 - 2019/05/09/ PY - 2019/5/10/pubmed PY - 2019/6/30/medline PY - 2019/5/10/entrez KW - Adverse effects KW - cardiovascular disease KW - statin-associated symptoms KW - statins KW - therapy SP - 573 EP - 579 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 18 IS - 7 N2 - INTRODUCTION: Although statins have a satisfactory safety profile and are well tolerated, many statin-treated patients report muscle symptoms in clinical practice which contribute to drug discontinuation and, consequently, adverse cardiovascular outcomes. AREAS COVERED: This narrative review will cover the definition and prevalence of statin intolerance, the clinical spectrum of statin-associated muscle symptoms (SAMS) with special focus on patients with only mild myalgias, the complexity of statin muscle intolerance diagnosis and provide an overview on the nocebo effect of particular importance for physicians. EXPERT OPINION: Many patients are unable to tolerate statin therapy, with SAMS being the most common cause of statin intolerance. The reported incidence of SAMS was consistently lower in randomized placebo-controlled trials than in observational studies. These results strongly suggested that SAMS were not always due to by the pharmacologic effects of statin therapy. Convincing patients that their muscle symptoms might be due to causes other than statin treatment is sometimes difficult. Furthermore, clinicians should not prematurely discontinue statin therapy before considering other possible causes, including the nocebo effect. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/31070941/Muscle_and_statins:_from_toxicity_to_the_nocebo_effect_ L2 - http://www.tandfonline.com/doi/full/10.1080/14740338.2019.1615053 DB - PRIME DP - Unbound Medicine ER -